CTOs on the Move

MyDental360

www.kulzerus.com

 
MyDental360 - Know what matters. Find what works. Powered by Kulzer The information you want on the subjects that affect your everyday work. We cover them from every angle—in a concise view delivered right to your inbox. Your Benefits • Busine...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Alvogen

Alvogen is a multinational, privately owned pharmaceuticals company focused on developing, manufacturing and distributing generic, brand, over-the-counter brands (OTC) and biosimilar products. With more than 200 pharmaceutical projects in development and registration, the group`s product portfolio consists of a broad range of leading molecules for the treatment of conditions in the fields of: oncology, cardiology, respiratory, neurology and gastroenterology. Alvogen has commercial operations in over 30 countries with 2,000 employees. North America is Alvogen`s single largest market and other key markets include: South-Korea, Romania, Bulgaria, Hungary, Taiwan, Russia and China.

Acadia Pharmaceuticals

Acadia Pharmaceuticals is a biopharmaceutical company that develops and commercializes therapies for central nervous system disorders. Their focus is on developing treatments for dementia-related psychosis, negative symptoms of schizophrenia, and Rett ...

Canadian International Pharmacy Association

Canadian International Pharmacy Association is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neuromed Pharmaceuticals

Neuromed Pharmaceuticals Ltd. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ophthotech

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech`s most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech`s second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD.